专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20150132273A1 Nutritional Compositions and Methods for Treating Cognitive Impairment 审中-公开
标题翻译：营养组合和治疗认知障碍的方法
公开(公告)号：US20150132273A1
公开(公告)日：2015-05-14
申请号：US14144012
申请日：2013-12-30
申请人： Rhett Sean Daniels
发明人： Rhett Sean Daniels
IPC分类号： A61K38/53 , A61K31/714 , A61K33/06 , A61K31/198 , A61K31/202 , A61K31/661 , A61K31/59 , A61K31/51 , A61K31/525 , A61K31/455 , A61K31/375 , A61K31/191 , A61K38/48 , A61K31/4525 , A61K31/7076 , A23L1/30 , A61K31/519
CPC分类号： A61K38/4873 , A23L33/10 , A23L33/12 , A23L33/15 , A23L33/16 , A23L33/17 , A61K9/0056 , A61K31/122 , A61K31/191 , A61K31/198 , A61K31/202 , A61K31/375 , A61K31/4525 , A61K31/455 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/59 , A61K31/593 , A61K31/661 , A61K31/685 , A61K31/7076 , A61K31/714 , A61K33/06 , A61K45/06 , C12Y304/22002 , A61K2300/00
摘要： A nutritional supplement that contains folinic acid, folic acid, USP, methylfolic acid, cobalamin, magnesium, docosahexaenoic acid, phosphatidylcholine-docosahexaenoic acid, phosphatidylethanolamine-docosahexaenoic acid.A nutritional supplement is disclosed for the treatment of cognitive disorders, attention deficit disorder, oxidative stress, depression, memory loss, anxiety, and apathy.
摘要翻译：含有亚叶酸，叶酸，USP，甲基叶酸，钴胺素，镁，二十二碳六烯酸，磷脂酰胆碱 - 二十二碳六烯酸，磷脂酰乙醇胺 - 二十二碳六烯酸的营养补充剂。公开了用于治疗认知障碍，注意力缺陷障碍，氧化应激，抑郁，记忆丧失，焦虑和冷漠的营养补充剂。

72. 发明授权

US08993547B2 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses 有权
标题翻译： 3-脱氧-2-亚甲基-19-维生素D类似物及其用途
公开(公告)号：US08993547B2
公开(公告)日：2015-03-31
申请号：US13495548
申请日：2012-06-13
申请人： Hector F. DeLuca , Lori A. Plum , Rafal R. Sicinski , Izabela Sibilska , Margaret Clagett-Dame
发明人： Hector F. DeLuca , Lori A. Plum , Rafal R. Sicinski , Izabela Sibilska , Margaret Clagett-Dame
IPC分类号： A61K31/59 , C07C401/00 , C07F9/02 , C07F9/53 , A61K31/593
CPC分类号： C07F9/5325 , A61K31/593 , C07C401/00 , C07C2601/14 , C07C2602/24 , C07F9/53
摘要： This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 and (20R)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.
摘要翻译：本发明公开了3-脱氧-2-亚甲基-19-去甲维生素D类似物，特别是（20S）-3-脱氧-2-亚甲基-1α，25-二羟基-19-去甲维生素D3和（20R） - 3-脱氧-2-亚甲基-1α，25-二羟基-19-去甲维生素D3以及其用途。这些化合物在阻止未分化细胞的增殖并诱导其分化为单核细胞方面表现出相对较高的结合活性和显着的活性，从而证明其用作抗癌剂，特别是用于治疗或预防骨肉瘤，白血病，结肠癌，乳腺癌，皮肤癌或前列腺癌。这些化合物还表现出相对较高的钙摄取活性，其用于治疗骨疾病。

73. 发明授权

US08987244B2 Preventing and/or treating cardiovascular disease and/or associated heart failure 有权
标题翻译：预防和/或治疗心血管疾病和/或相关的心力衰竭
公开(公告)号：US08987244B2
公开(公告)日：2015-03-24
申请号：US14029984
申请日：2013-09-18
申请人： PhilERA New Zealand Limited
发明人： Garth J. S. Cooper , John R. Baker
IPC分类号： A61K38/00 , A61K31/315 , A61K31/195 , A61K31/185 , A61K31/59 , A61K33/30 , A61K31/197 , A61K31/13 , A61K31/198 , A61K31/30 , A61K31/38 , A61K31/45 , A61K33/34 , A61K45/06
CPC分类号： A61K31/197 , A61K31/13 , A61K31/198 , A61K31/30 , A61K31/38 , A61K31/45 , A61K33/30 , A61K33/34 , A61K45/06
摘要： Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
摘要翻译：提供了用于减少铜值的方法，例如，治疗，预防或改善组织损伤，例如可能由（i）心脏病（例如心肌病或心肌炎）引起的组织损伤，例如特发性心肌病，包括糖尿病性心肌病，酒精性心肌病，药物性心肌病，缺血性心肌病，高血压性心肌病等的代谢性心肌病，（ii）主要血管（大血管病）如动脉粥样硬化性疾病如冠状动脉，颈动脉，脑血管动脉，肾动脉，髂动脉，股动脉和al动脉，（iii）药物诱导和代谢（包括小血管（微血管病）的高血压和/或糖尿病性疾病）作为视网膜小动脉，肾小球小动脉，神经伏脉，心脏小动脉和相关毛细血管床 e眼，肾脏，心脏和中枢和周围神经系统，（iv）主要血管（如主动脉，冠状动脉，颈动脉，脑血管动脉，肾动脉）的动脉粥样硬化病变的斑块破裂，髂动脉，股动脉和al动脉，（v）糖尿病或糖尿病并发症。

74. 发明授权

US08987235B2 N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs and their uses 有权
标题翻译： N-环丙基 - （20R）-2-亚甲基-19,26,27-三硝基-25-氮杂 - 维生素D类似物及其用途
公开(公告)号：US08987235B2
公开(公告)日：2015-03-24
申请号：US13473259
申请日：2012-05-16
申请人： Hector F. DeLuca , Margaret Clagett-Dame , Lori A. Plum , Grazia Chiellini
发明人： Hector F. DeLuca , Margaret Clagett-Dame , Lori A. Plum , Grazia Chiellini
IPC分类号： A61K31/59 , C07C401/00 , C07C211/03 , C07C271/24 , C07C215/42 , C07C225/10 , C07F7/18
CPC分类号： C07C401/00 , C07C215/42 , C07C225/10 , C07C271/24 , C07C2601/02 , C07C2601/14 , C07C2602/24 , C07F7/1804
摘要： This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.
摘要翻译：本发明公开了N-环丙基 - （20R）-2-亚甲基-19,26,27-三硝基-25-氮杂 - 维生素D类似物，特别是N-环丙基 - （20R）-2-亚甲基-19,26,27 - 紫霉素-25-氮杂-1α-羟基维生素D3及其药物用途。该化合物在阻止未分化细胞的增殖和诱导其分化为单核细胞方面表现出相对较高的结合活性和明显的活性，从而证明其用作抗癌剂，特别是用于治疗或预防白血病，结肠癌，乳腺癌，皮肤癌或前列腺癌。

75. 发明授权

US08962000B2 Microemulsion and sub-micron emulsion process and compositions 有权
标题翻译：微乳液和亚微米乳液工艺及组成
公开(公告)号：US08962000B2
公开(公告)日：2015-02-24
申请号：US13873777
申请日：2013-04-30
申请人： Stiefel Research Australia Pty Ltd
发明人： Maria Graziella Larm , Ronald Harding , Michael Johnston , Albert Zorko Abram , Prema Viyayakumar , Phoebe Sun
IPC分类号： A61K9/00 , A61K8/02 , A01N45/00 , A61K31/59 , A61K31/56 , A61K9/107 , A61K8/06
CPC分类号： A61K9/1075 , A61K8/062 , A61K8/068 , A61K8/31 , A61K8/37 , A61K8/585 , A61K8/63 , A61K8/86 , A61K8/92 , A61K8/922 , A61K31/56 , A61K31/58 , A61K31/59 , Y10S514/937
摘要： An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.
摘要翻译：提供了一种用于皮肤递送至少一种药物活性成分的水包油微乳液或亚微米乳液组合物。所述组合物包括分散在水相中的油相，所述油相包含选自动物油，矿物油，植物油，硅烷组分，硅氧烷，酯，脂肪中的至少一种酸，脂肪，卤素化合物和烷氧基化醇; 和至少一种亲脂性表面活性剂，所述水相包括至少一种亲水性表面活性剂，水和任选的非表面活性剂两亲性化合物，所述至少一种亲水性表面活性剂与至少一种亲脂性表面活性剂的重量比为约9.0:1.0至约 2.0：3.0。

76. 发明申请

US20150037438A1 CHEWABLE GELLED EMULSIONS 有权
标题翻译：可咀嚼的乳胶
公开(公告)号：US20150037438A1
公开(公告)日：2015-02-05
申请号：US14515297
申请日：2014-10-15
申请人： Tore SETERNES , Kurt Ingar Draget , Ingvild Johanne Haug
发明人： Tore SETERNES , Kurt Ingar Draget , Ingvild Johanne Haug
IPC分类号： A61K9/00 , A61K9/107 , A61K47/14 , A61K47/42 , A61K47/36 , A61K47/10 , A61K47/22 , A61K47/20 , A61K31/7135 , A61K33/10 , A61K31/59 , A61K31/714 , A61K31/51 , A61K31/525 , A61K31/675 , A61K31/519 , A61J1/03 , A61K31/192
CPC分类号： A61K9/0056 , A61J1/035 , A61K9/107 , A61K31/00 , A61K31/192 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/59 , A61K31/675 , A61K31/7135 , A61K31/714 , A61K33/10 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/36 , A61K47/42
摘要： An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.
摘要翻译：一种单位剂量形式的口服药物组合物，每个单位剂量在单一载体体内包含亲脂性药物物质，所述体包含软的咀嚼胶凝的水包油乳液。

77. 发明授权

US08933028B2 Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue 有权
标题翻译：选择性雌激素受体调节剂用于关节融合和其他修复或愈合的结缔组织
公开(公告)号：US08933028B2
公开(公告)日：2015-01-13
申请号：US13934344
申请日：2013-07-03
申请人： John G. Stark
发明人： John G. Stark
IPC分类号： A61K38/00 , A61K31/4535 , A61K31/138 , A61K31/40 , A61K31/4025 , A61K31/55 , A61K31/56 , A61K33/06 , A61K38/18 , A61K45/06 , A61K31/59 , A61K38/19
CPC分类号： A61K31/4535 , A61K31/138 , A61K31/40 , A61K31/4025 , A61K31/55 , A61K31/56 , A61K31/59 , A61K33/06 , A61K38/1841 , A61K38/1875 , A61K38/19 , A61K45/06 , A61K2300/00
摘要： Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient.
摘要翻译：公开了使用选择性雌激素受体调节剂（SERM）如雷洛昔芬促进关节固定或融合的方法。 SERM可以系统地或局部施用。与SERM一起，可以同时施用其他治疗剂如钙，维生素D，骨形态发生蛋白。该方法可以类似地应用于促进患者中的骨修复，骨愈合和结缔组织愈合过程。

78. 发明授权

US08889840B2 Vascular leakage inhibitor 有权
标题翻译：血管渗漏抑制剂
公开(公告)号：US08889840B2
公开(公告)日：2014-11-18
申请号：US13504368
申请日：2010-10-29
申请人： Young-Guen Kwon , Young-Ger Suh
发明人： Young-Guen Kwon , Young-Ger Suh
IPC分类号： C07J41/00 , C07J17/00 , A01N45/00 , A61K31/59 , A61K31/58 , A61K31/56 , C07D309/12 , C07D239/34 , C07D309/30 , C07D309/10 , C07D303/22
CPC分类号： C07D309/12 , C07D239/34 , C07D303/22 , C07D309/10 , C07D309/30 , C07J9/00 , C07J9/005 , C07J17/00 , C07J17/005 , C07J31/006 , C07J41/0055 , C07J43/003
摘要： The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.
摘要翻译：本公开涉及一种新型血管渗漏抑制剂。本公开的新型血管渗漏抑制剂抑制血管内皮细胞的凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，增强皮层肌动蛋白环结构，并改善血管细胞之间紧密连接（TJ）的稳定性，从而抑制血管渗漏。本公开的血管渗漏抑制剂具有不仅降低血管渗透性，而且恢复受损血管完整性的活性。因此，本公开的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本公开的血管渗漏抑制剂由市售或容易合成的胆固醇合成，因此具有商业合成的显着优异的可行性。

79. 发明授权

US08889426B2 Methods of identifying inhibitors of FGF23 binding to the binary FGFR-klotho complex for the treatment of hypophosphatemia 有权
标题翻译：鉴定与二元FGFR-klotho复合物结合的FGF23抑制剂用于治疗低磷血症的方法
公开(公告)号：US08889426B2
公开(公告)日：2014-11-18
申请号：US13475094
申请日：2012-05-18
申请人： Moosa Mohammadi , Regina Goetz , Anna V. Eliseenkova
发明人： Moosa Mohammadi , Regina Goetz , Anna V. Eliseenkova
IPC分类号： G01N33/53 , A61K38/17 , G01N33/68 , G01N33/573 , A61K45/06 , G01N21/84 , G01N30/00 , A61K31/59 , C07K14/50
CPC分类号： A61K38/1825 , A61K31/59 , A61K38/17 , A61K38/1709 , A61K45/06 , G01N21/84 , G01N30/00 , G01N33/573 , G01N33/68
摘要： The present invention is directed to a method of treating hypophosphatemia in a subject. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed.
摘要翻译：本发明涉及治疗受试者中低磷酸血症的方法。本发明还涉及筛选适合于治疗与升高或正常FGF23相关的低磷血症的化合物的方法。该方法包括提供FGF23，FGFR-Klotho复合物和一种或多种候选化合物。 FGF23，FGFR-Klotho复合物和候选化合物在对FGF23和二元FGFR-Klotho复合物有效的条件下合并，以形成三元复合物（如果存在）。该方法还涉及鉴定候选化合物，其防止复合物形成潜在地适合于治疗与升高或正常FGF23相关的低磷血症。还公开了筛选防止FGF23-Klotho-FGFR复合物形成的化合物特异性的方法。

80. 发明申请

US20140329782A1 COMBINED THERAPEUTIC AGENT 审中-公开
标题翻译：联合治疗药物
公开(公告)号：US20140329782A1
公开(公告)日：2014-11-06
申请号：US14239610
申请日：2012-08-19
申请人： Anna Mai Joy Juergens , Heike Juergens , Lisa Joy Juergens
发明人： Anna Mai Joy Juergens , Heike Juergens , Lisa Joy Juergens
IPC分类号： A61K31/59 , A61K31/167 , A61K31/58
CPC分类号： A61K31/59 , A61K31/045 , A61K31/137 , A61K31/164 , A61K31/167 , A61K31/35 , A61K31/4174 , A61K31/4178 , A61K31/505 , A61K31/573 , A61K31/58 , A61K31/592 , A61K31/593 , A61K31/728 , A61K2300/00
摘要： The invention relates to a combined therapeutic agent, preferably for use at the prophylactic and/or therapeutic treatment of (A) in particular inflammatory diseases of the respiratory tract, in particular bronchopulmonary diseases, or of (B) in particular inflammatory diseases of the gastrointestinal tract, in particular of the intestine. The combined therapeutic agent comprises at least one vitamin D receptor agonist (VDA) and at least one further active substance, provided that the combined therapeutic agent does not contain any constituent and/or active substance from the group consisting of terpenes, monoterpenes, vasoconstrictors, alpha sympathomimetics and/or the physiologically harmless salts or derivatives thereof.
摘要翻译：本发明涉及组合治疗剂，优选用于预防和/或治疗（A）特别是呼吸道炎症性疾病，特别是支气管肺疾病，或（B）特别是胃肠道炎症性疾病肠道，特别是肠道。组合的治疗剂包含至少一种维生素D受体激动剂（VDA）和至少一种其它活性物质，条件是组合的治疗剂不含有来自萜烯，单萜，血管收缩剂， α拟交感神经药和/或其生理上无害的盐或其衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式